Promising lymphoma combo trial pulled before it even started
NCT ID NCT04285268
First seen Feb 01, 2026 · Last updated Apr 29, 2026 · Updated 14 times
Summary
This study was designed to test whether combining three drugs—rituximab, venetoclax, and bortezomib—could shrink or stop the growth of an aggressive type of lymphoma (DLBCL) that had come back or not responded to prior treatment. The trial was withdrawn before enrolling any participants, so no results are available. The approach aimed to use immunotherapy and targeted drugs to attack cancer cells in different ways.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT DIFFUSE LARGE B-CELL LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903, United States
Conditions
Explore the condition pages connected to this study.